Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Anum BabarMaham BabarHina ZubairArzu ShahidSana RafiqueMaimona BanoMadeeha Subhan WaleedMaimoona KhanArslan InayatDanish SafiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
To improve the outcome of patients with relapsed/refractory multiple myeloma, it is critical to develop new therapies, assess potential therapeutic synergies, and overcome drug resistance by determining the efficacy of multiple myeloma therapies across multiple disease subgroups.